Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 5/2008

01-05-2008 | Review

Beta cell mass in diabetes: a realistic therapeutic target?

Author: J. J. Meier

Published in: Diabetologia | Issue 5/2008

Login to get access

Abstract

Beta cell deficiency underlies both type 1 and type 2 diabetes, and restoration or replacement of beta cell function is therefore the logical long-term solution to therapy. This review sets out to describe the defects in beta cell mass and function in both forms of diabetes, summarises current understanding of the underlying causes of beta cell death, and the methodological limitations of determining beta cell mass in vivo. Finally, the potential effects of current and future treatment regimens on beta cell mass and turnover are considered.
Literature
1.
Gepts W (1965) Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 14:619–663PubMed
2.
Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC (2005) Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 48:2221–2228PubMedCrossRef
3.
Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110PubMedCrossRef
4.
Meier JJ, Bhushan A, Butler PC (2006) The potential for stem cell therapy in diabetes. Pediatr Res 59:65R–73RPubMedCrossRef
5.
Robertson RP (2000) Successful islet transplantation for patients with diabetes—fact or fantasy? N Engl J Med 343:289–290PubMedCrossRef
6.
Ryan EA, Paty BW, Senior PA et al (2005) Five-year follow-up after clinical islet transplantation. Diabetes 54:2060–2069PubMedCrossRef
7.
Robertson RP (2004) Islet transplantation as a treatment for diabetes—a work in progress. N Engl J Med 350:694–705PubMedCrossRef
8.
Meier JJ, Butler PC (2005) Insulin secretion. In: DeGroot LJ, Jameson JL (eds) Endocrinology, 5th edn. Elsevier Saunders, Philadelphia, pp 961–973
9.
Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595–1607PubMedCrossRef
10.
Shaper AG, Wannamethee SG, Walker M (1997) Body weight: implications for the prevention of coronary heart disease, stroke, and diabetes mellitus in a cohort study of middle aged men. BMJ 314:1311–1317PubMed
11.
Perley MJ, Kipnis DM (1967) Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 46:1954–1962PubMed
12.
Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr (1984) Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 74:1318–1328PubMedCrossRef
13.
Polonsky KS, Given BD, Hirsch LJ et al (1988) Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 318:1231–1239PubMedCrossRef
14.
Gerich JE (1998) The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 19:491–503PubMedCrossRef
15.
Kruszynska YT, Home PD (1987) Insulin insensitivity in type 1 diabetes. Diabet Med 4:414–422PubMed
16.
Kjems LL, Kirby BM, Welsh EM et al (2001) Decrease in beta-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig. Diabetes 50:2001–2012PubMedCrossRef
17.
Kendall DM, Sutherland DE, Najarian JS, Goetz FC, Robertson RP (1990) Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans. N Engl J Med 322:898–903PubMedCrossRef
18.
Meier JJ, Kjems LL, Veldhuis JD, Lefèbvre P, Butler PC (2006) Post prandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: Further evidence for the intraislet insulin hypothesis. Diabetes 55:1051–1056PubMedCrossRef
19.
Matveyenko AV, Butler PC (2006) Beta-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes. Diabetes 55:2106–2114PubMedCrossRef
20.
Pox C, Ritzel R, Busing M et al (2002) Combined pancreas and kidney transplantation in a lean type 2 diabetic patient. Effects on insulin secretion and sensitivity. Exp Clin Endocrinol Diabetes 110:420–424PubMedCrossRef
21.
Nath DS, Gruessner AC, Kandaswamy R, Gruessner RW, Sutherland DE, Humar A (2005) Outcomes of pancreas transplants for patients with type 2 diabetes mellitus. Clin Transplant 19:792–797PubMedCrossRef
22.
Marchetti P, Del Guerra S, Marselli L et al (2004) Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab 89:5535–5541PubMedCrossRef
23.
Robertson RP, Harmon J, Tran PO, Poitout V (2004) Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 53(Suppl 1):S119–S124PubMedCrossRef
24.
Bonner-Weir S, Trent DF, Weir GC (1983) Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J Clin Invest 71:1544–1553PubMedCrossRef
25.
Boden G, Chen X, Rosner J, Barton M (1995) Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes 44:1239–1242PubMedCrossRef
26.
Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC (1999) The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48:491–498PubMedCrossRef
27.
Robertson RP (2004) Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem 279:42351–42354PubMedCrossRef
28.
Laybutt DR, Preston AM, Akerfeldt MC et al (2007) Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes. Diabetologia 50:752–763PubMedCrossRef
29.
Maedler K, Storling J, Sturis J et al (2004) Glucose- and interleukin-1β-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets. Diabetes 53:1706–1713PubMedCrossRef
30.
Ritzel RA, Butler AE, Rizza RA, Veldhuis JD, Butler PC (2006) Relationship between beta-cell mass and fasting blood glucose concentration in humans. Diabetes Care 29:717–718PubMedCrossRef
31.
Kloppel G, Drenck CR, Oberholzer M, Heitz PU (1984) Morphometric evidence for a striking B cell reduction at the clinical onset of type 1 diabetes. Virchows Arch A Pathol Anat Histopathol 403:441–452PubMedCrossRef
32.
Tsai EB, Sherry NA, Palmer JP, Herold KC (2006) The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia 49:261–270PubMedCrossRef
33.
Madsbad S (1983) Prevalence of residual B cell function and its metabolic consequences in type 1 (insulin-dependent) diabetes. Diabetologia 24:141–147PubMed
34.
Pipeleers D, Ling Z (1992) Pancreatic beta cells in insulin-dependent diabetes. Diabetes Metab Rev 8:209–227PubMed
35.
Butler AE, Galasso R, Meier JJ, Basu R, Rizza RA, Butler PC (2007) Modestly increased beta cell apoptosis but no increased beta cell replication in recent-onset type 1 diabetic patients who died of diabetic ketoacidosis. Diabetologia 50:2323–2331PubMedCrossRef
36.
Meier JJ, Lin JC, Butler AE, Galasso R, Martinez DS, Butler PC (2006) Direct evidence of attempted beta cell regeneration in an 89-year old patient with recent onset type 1 diabetes. Diabetologia 49:1838–1844PubMedCrossRef
37.
The Diabetes Control and Complications Trial Research Group (1987) Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 65:30–36CrossRef
38.
Sreenan S, Pick AJ, Levisetti M, Baldwin AC, Pugh W, Polonsky KS (1999) Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes 48:989–996PubMedCrossRef
39.
Lohr M, Kloppel G (1987) Residual insulin positivity and pancreatic atrophy in relation to duration of chronic type 1 (insulin-dependent) diabetes mellitus and microangiopathy. Diabetologia 30:757–762PubMedCrossRef
40.
Madsbad S, Krarup T, Reguer L, Faber OK, Binder C (1981) Effect of strict blood glucose control on residual B cell function in insulin-dependent diabetics. Diabetologia 20:530–534PubMedCrossRef
41.
The Diabetes Control and Complications Trial Research Group (1998) Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 128:517–523
42.
Chatenoud L, Thervet E, Primo J, Bach JF (1994) Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 91:123–127PubMedCrossRef
43.
Pfeifer MA, Halter JB, Porte D Jr (1981) Insulin secretion in diabetes mellitus. Am J Med 70:579–588PubMedCrossRef
44.
Bruttomesso D, Pianta A, Mari A et al (1999) Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 48:99–105PubMedCrossRef
45.
Pørksen N, Nyholm B, Veldhuis JD, Butler PC, Schmitz O (1997) In humans at least 75% of insulin secretion arises from punctuated insulin secretory bursts. Am J Physiol 273:E908–E914PubMed
46.
Matschinsky F, Liang Y, Kesavan P et al (1993) Glucokinase as pancreatic beta cell glucose sensor and diabetes gene. J Clin Invest 92:2092–2098PubMedCrossRef
47.
Zhou H, Tran PO, Yang S et al (2004) Regulation of alpha-cell function by the beta-cell during hypoglycemia in Wistar rats: the “switch-off” hypothesis. Diabetes 53:1482–1487PubMedCrossRef
48.
D’Amour KA, Bang AG, Eliazer S et al (2006) Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol 24:1392–1401PubMedCrossRef
49.
Karlsson S, Scheurink AJ, Steffens AB, Ahren B (1994) Involvement of capsaicin-sensitive nerves in regulation of insulin secretion and glucose tolerance in conscious mice. Am J Physiol 267:R1071–R1077PubMed
50.
Samols E, Stagner JI, Ewart RB, Marks V (1988) The order of islet microvascular cellular perfusion is B–A–D in the perfused rat pancreas. J Clin Invest 82:350–353PubMedCrossRef
51.
King AJ, Fernandes JR, Hollister-Lock J, Nienaber CE, Bonner-Weir S, Weir GC (2007) Normal relationship of beta- and non-beta-cells not needed for successful islet transplantation. Diabetes 56:2312–2318PubMedCrossRef
52.
Sorenson RL, Brelje TC (1997) Adaptation of islets of Langerhans to pregnancy: beta-cell growth, enhanced insulin secretion and the role of lactogenic hormones. Horm Metab Res 29:301–307PubMedCrossRef
53.
54.
Van Assche FA, Aerts L, De Prins F (1978) A morphological study of the endocrine pancreas in human pregnancy. Br J Obstet Gynaecol 85:818–820PubMed
55.
Hellerstrom C, Swenne I (1991) Functional maturation and proliferation of fetal pancreatic beta-cells. Diabetes 40(Suppl 2):89–93PubMed
56.
Scaglia L, Cahill CJ, Finegood DT, Bonner-Weir S (1997) Apoptosis participates in the remodeling of the endocrine pancreas in the neonatal rat. Endocrinology 138:1736–1741PubMedCrossRef
57.
Dor Y, Brown J, Martinez OI, Melton DA (2004) Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429:41–46PubMedCrossRef
58.
Butler AE, Janson J, Soeller WC, Butler PC (2003) Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 52:2304–2314PubMedCrossRef
59.
Teta M, Long SY, Wartschow LM, Rankin MM, Kushner JA (2005) Very slow turnover of β-cells in aged adult mice. Diabetes 54:2557–2567PubMedCrossRef
60.
Finegood DT, Scaglia L, Bonner-Weir S (1995) Dynamics of beta-cell mass in the growing rat pancreas. Estimation with a simple mathematical model. Diabetes 44:249–256PubMedCrossRef
61.
Meier JJ, Butler AE, Galasso R, Butler PC (2006) Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover. Diabetes Care 29:1554–1559PubMedCrossRef
62.
Meier JJ, Butler AE, Galasso R, Rizza RA, Butler PC (2006) Increased islet beta cell replication adjacent to intrapancreatic gastrinomas in humans. Diabetologia 48:2689–2696CrossRef
63.
Bonner-Weir S, Baxter LA, Schuppin GT, Smith FE (1993) A second pathway for regeneration of adult exocrine and endocrine pancreas. A possible recapitulation of embryonic development. Diabetes 42:1715–1720PubMedCrossRef
64.
Bouwens L, Pipeleers DG (1998) Extra-insular beta cells associated with ductules are frequent in adult human pancreas. Diabetologia 41:629–633PubMedCrossRef
65.
Bonner-Weir S (2001) Beta-cell turnover: its assessment and implications. Diabetes 50(Suppl 1):S20–S24PubMedCrossRef
66.
Peshavaria M, Larmie BL, Lausier J et al (2006) Regulation of pancreatic beta-cell regeneration in the normoglycemic 60% partial-pancreatectomy mouse. Diabetes 55:3289–3298PubMedCrossRef
67.
Bonner-Weir S, Deery D, Leahy JL, Weir GC (1989) Compensatory growth of pancreatic beta-cells in adult rats after short-term glucose infusion. Diabetes 38:49–53PubMedCrossRef
68.
Xu G, Stoffers DA, Habener JF, Bonner-Weir S (1999) Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270–2276PubMedCrossRef
69.
Bouwens L, Lu WG, De Krijger R (1997) Proliferation and differentiation in the human fetal endocrine pancreas. Diabetologia 40:398–404PubMedCrossRef
70.
Chen S, Turner SM, Tsang E et al (2007) Measurement of pancreatic islet cell proliferation by heavy water labeling. Am J Physiol Endocrinol Metab 293:E1459–E1464PubMedCrossRef
71.
72.
Polonsky KS, Given BD, Hirsch L et al (1988) Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest 81:435–441PubMedCrossRef
73.
Fehse F, Trautmann M, Holst JJ et al (2005) Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 90:5991–5997PubMedCrossRef
74.
Laedtke T, Kjems L, Porksen N et al (2000) Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. Am J Physiol 279:E520–E528
75.
Cusi K, Cunningham GR, Comstock JP (1995) Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. Diabetes Care 18:843–851PubMedCrossRef
76.
Meier JJ, Veldhuis JD, Butler PC (2005) Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Diabetes 54:1649–1656PubMedCrossRef
77.
Robertson RP (2007) Estimation of beta-cell mass by metabolic tests: necessary, but how sufficient? Diabetes 56:2420–2424PubMedCrossRef
78.
Teuscher AU, Kendall DM, Smets YF, Leone JP, Sutherland DE, Robertson RP (1998) Successful islet autotransplantation in humans: functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes 47:324–330PubMedCrossRef
79.
Ryan EA, Lakey JR, Paty BW et al (2002) Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 51:2148–2157PubMedCrossRef
80.
Efanova IB, Zaitsev SV, Zhivotovsky B et al (1998) Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration. J Biol Chem 273:33501–33507PubMedCrossRef
81.
Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY (2005) Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 90:501–506PubMedCrossRef
82.
Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC (1998) UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 15:297–303PubMedCrossRef
83.
Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2443PubMedCrossRef
84.
Farilla L, Bulotta A, Hirshberg B et al (2003) Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144:5149–5158PubMedCrossRef
85.
Ritzel RA, Hansen JB, Veldhuis JD, Butler PC (2004) Induction of β-cell rest by a Kir6.2/SUR1-selective KATP-channel opener preserves β-cell insulin stores and insulin secretion in human islets cultured at high (11 mM) glucose. J Clin Endocrinol Metab 89:795–805PubMedCrossRef
86.
Huang CJ, Lin CY, Haataja L et al (2007) High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes 56:2016–2027PubMedCrossRef
87.
Alvarsson M, Sundkvist G, Lager I et al (2003) Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 26:2231–2237PubMedCrossRef
88.
Herold KC, Hagopian W, Auger JA et al (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346:1692–1698PubMedCrossRef
89.
Carel JC, Boitard C, Eisenbarth G, Bach JF, Bougneres PF (1996) Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre-type 1 diabetic children. J Autoimmun 9:739–745PubMedCrossRef
90.
Hoorens A, Pipeleers D (1999) Nicotinamide protects human beta cells against chemically-induced necrosis, but not against cytokine-induced apoptosis. Diabetologia 42:55–59PubMedCrossRef
91.
Bjork E, Berne C, Kampe O, Wibell L, Oskarsson P, Karlsson FA (1996) Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 45:1427–1430PubMedCrossRef
92.
Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50:259–267PubMedCrossRef
93.
Ghofaili KA, Fung M, Ao Z et al (2007) Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation 83:24–28PubMedCrossRef
94.
Pospisilik JA, Martin J, Doty T et al (2003) Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52:741–750PubMedCrossRef
95.
Ahren B, Gomis R, Standl E, Mills D, Schweizer A (2004) Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27:2874–2880PubMedCrossRef
96.
Hull RL, Shen ZP, Watts MR et al (2005) Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide. Diabetes 54:2235–2244PubMedCrossRef
97.
Lin CY, Gurlo T, Haataja L, Hsueh WA, Butler PC (2005) Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3′-kinase-dependent pathway. J Clin Endocrinol Metab 90:6678–6686PubMedCrossRef
98.
Lupi R, Del Guerra S, Bugliani M et al (2006) The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets. Eur J Endocrinol 154:355–361PubMedCrossRef
99.
Gerstein HC, Yusuf S, Bosch J et al (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096–1105PubMedCrossRef
Metadata
Title
Beta cell mass in diabetes: a realistic therapeutic target?
Author
J. J. Meier
Publication date
01-05-2008
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 5/2008
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-008-0936-9

Other articles of this Issue 5/2008

Diabetologia 5/2008 Go to the issue

Research Letter

Marked temporal increase in the incidence of type 1 and type 2 diabetes among young adults in Finland

Letter

Studies of regional adipose transplantation reveal a unique and beneficial interaction between subcutaneous adipose tissue and the intra-abdominal compartment

Article

Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2

Editorial

Who needs the diabetes specialist physician?

Article

A Kir6.2 mutation causing severe functional effects in vitro produces neonatal diabetes without the expected neurological complications

Article

Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits